Marker Therapeutics Inc is a biopharmaceutical company focused on the development of innovative immunotherapy treatments for cancer
The company specializes in creating personalized T cell therapies designed to harness the body's immune system to target and eliminate tumors. By utilizing a unique approach that enhances T cell functionality, Marker Therapeutics aims to provide more effective treatment options for various types of malignancies, contributing to advancements in oncology and improving patient outcomes through precision medicine.
Marker Therapeutics Inc (NASDAQMRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline.
Marker Therapeutics Inc (NASDAQMRKR) released the preliminary results of the first participant treated with MT-601, its multi-tumor associated antigen (multiTAA)-specific T cell product targeting 6 TAAs, in the Phase 1 multicenter
Gainers Crinetics Pharmaceuticals, Inc. (NASDAQCRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study in acromegaly.
Gainers Yellow Corporation (NASDAQYELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report.
Marker Therapeutics, Inc. (NASDAQMRKR) shares are trading higher by 18.7% to $5.15 Monday morning after the company announced the European Medicines Agency granted MT-401 an
U.S. stocks traded higher toward the end of trading, with Nasdaq Composite gaining over 100 points on Monday. The Dow traded up 0.19% to 33,939.74 while the NASDAQ rose 1% to 13,391.54. The S&P 500, also rose, gaining, 0.47% to 4,319.22.
Gainers Mobilicom Limited (NASDAQMOB) shares jumped 81.3% to $2.7187 after the company announced it received a commercial scale purchase order from Teledyne-FLIR for the production of drones for the U.S. Department of Defense.
Gainers First Wave BioPharma, Inc. (NASDAQFWBI) shares gained 143% to $2.77 after the company achieved its enrollment target for its adrulipase Phase 2 SPAN trial for exocrine pancreatic insufficiency in cystic fibrosis patients.
